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In English
The European Commission is preparing legislation with
regard to advanced therapies  created by new technology.1
The legislation deals with gene therapy, cell therapy, tissue
engineering and other new technologies which support
these. The draft  proposal of the Commission concerning
the supervision of products and the associated marketing
authorisation procedures has been made available for com-
ments from all interested parties.
It is reckoned that the products of new technology will
have a significant impact on health care, and the products
have several scientific, economic and ethical aspects in com-
mon. The products are based on complicated, high-tech
manufacturing processes, the scientific and supervisory
expertise in the product area is scarce, and protection against
infection is one of the key issues of safety. These products are
often developed by small and medium-sized biotechnology
firms.
The new advanced therapies  are expected to be of signif-
icant benefit in, for example, the treatment of cancer, as well
as the treatment of Alzheimer’s and Parkinson’s diseases.
Regenerative medicine, by which disease paths are changed
and which may in the end make it possible to grow tissues
topically in the human body, is also a current focus of atten-
tion. The new therapies are presumably more costly than
conventional drug therapies. In view of the tight monetary
framework of health care this aspect will also no doubt make
prioritisation and more rational drug treatment necessary.
The aim of the new supervisory measures is to ensure a
high level of safety for patients. The prerequisites for product
introductions on to the market, and the supervision of the
safety of products already available on the market, will be
harmonised. The aim is also to improve the preconditions of
competition among companies operating in Europe and to
ensure flexibility at a level of regulation adequate for scientif-
ic and technological development.
Safety is also being improved in other ways. A Directive
on human tissue2 was approved in March 2004, the aim of
which is to ensure the quality and safety of human tissues
and cells to be used in humans. The Directive will be
enforced nationally by 7.4.2006. The Directive deals, for
example, with the supervision of procurement of human tis-
sues and cells, as well as the accreditation, licenses  and
inspections of tissue institutions. The stem cells of adults
and embryos also fall within the scope of application of the
Directive. It is proposed that the National Agency for Medi-
cines takes on the role of a supervisory authority in respect
of ‘tissue institutions’, i.e. tissue banks.
New therapeutic alternatives are associated with known
and also unexpected risks. The best known ones probably
include microbiological contamination of source materials
and production processes, including the spread of diseases,
natural variation in the source materials, incompatibility of
bio-materials and tumorogenicity of products. The National
Agency for Medicines in Finland has submitted a review to
the Ministry of Social Affairs and Health on the ‘safety of
products containing material of human origin’.
The requirements and measures of modern pharmaceuti-
cal supervision have developed during the past 40 years. The
intention is, in fact, to make use of the experience gained
thereby in the supervision of tissue engineering products. It
appears that the European Medicines Agency (EMEA) will
assume a new duty role in the scientific evaluation of tissue
engineering products. This would have a natural reflection in
the requirements for expertise of the competent authorities
for pharmaceuticals in each Member State, as all these
authorities already work in close collaboration with the
EMEA.
The development of products containing material of
human origin is a growing sector of technology. Products are
already available commercially worldwide. Scientific and
technological development will not, however, wait for
legislative developments, and supervision would also require
new ways of thinking. It would be in the best interest of the
patients, the development of the sector, and the industry, if
the supervisory arrangements were created at an early stage.
This would dispel the uncertainties associated with safety
requirements, promote the development and competitiveness
of companies and expedite the introduction of the new
products into health and patient care.
1 http://pharmacos.eudra.org/F2/advtherapies/index.htm
2 Official Journal of the European Union L102, 7.4.2004, p.
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Recommendations for the medical therapy 
of the elderly
Changes in the human body associated
with ageing also change the absorpt-
ion, distribution, degradation and
elimination of drugs. The proportion
of water of the total body weight is
decreasing and the proportion of fat is
increasing. The distribution volume of
fat-soluble medicinal substances is
increasing and their elimination is
decreasing. The distribution volume of
water-soluble medicinal substances is
decreasing. The hepatic circulation is
reduced, and the function of some
drug catalysing enzymes is also
reduced. The capacity of the kidneys
to secrete medicinal substances and the
products of their degradation is
reduced and is at the age of 75–80
about half of the secretion capacity of
a young adult (1). Creatinine produc-
tion is reduced as the muscle mass is
decreasing, and the serum creatinine
concentration therefore poorly reflects
the renal function of the elderly. Crea-
tinine clearance and serum cystatine C
concentration are superior methods of
assaying this (2).
The sensitivity of tissues and cells
to drug effects is increased, and the
capacity to tolerate the harmful side-
effects of drugs is reduced. The elderly
are especially predisposed to the brain
function reducing adverse effects of
benzodiazepines, opioids, anticholiner-
gic agents and antipsychotic drugs,
such as impairment of the memory
and other cognitive abilities, and con-
fusion. Reduced baroreceptor reflex
predisposes them to the development
of ortostatic hypotension, for example
when vasodilators, diuretics, anti-
Parkinson drugs, antipsychotics or tri-
cyclic antidepressants are used (1).
Attempts to solve the problems
associated with medical treatment of
the elderly have been made in many
countries by arranging further training
for doctors and other health care
employees and by employing experts in
clinical pharmacy at care institutions
(3). The experts have issued guidelines
for the clinical use and general evalua-
tion of medical treatment (4, 5, 6, 7).
Furthermore, in the USA, the use of
antipsychotics in long-term care insti-
tutions has been restricted. The moni-
toring of practices in the medical treat-
ment at care institutions shows that, in
long-term care institutions, the use of
drugs under regulatory restrictions is
relatively rare (8, 9, 10).
In this paper we discuss the general
recommendations for medical
treatment of the elderly issued by a
Swedish group of experts (7). We also
discuss some of the general problems
associated with medical treatment of
the elderly in Finland, and suggest
measures which we consider necessary.
Expert recommendations
The expert recommendations issued in
Sweden stipulate which medicines
should be avoided in the treatment of
the elderly, the length of time for
which certain medicines may be given,
the ways in which the effects and
adverse reactions of the substances
should be monitored, and which sub-
stance combinations to avoid. These
guidelines are thus concerned with
medicinal substances and do not con-
stitute instructions for the treatment of
diseases. In addition to the general
guidelines, recommendations for drug
therapies in some diseases are also
given. The general recommendations,
which are not specific to any particular
disease, are based on international rec-
ommendations and differ scarcely at all
from the guidelines given in other
countries (7).
Medicines to be avoided with-
out a special consideration 
Medicines with a long half-life, such as
benzodiazepine derivatives i.e.
diazepam, chlordiazepoxide and
nitrazepam, highly anticholinergic
agents, oral theophylline and quinine
are agents which should be avoided in
the treatment of the elderly (7). 
Fat-soluble medicinal substances
have a longer half-life in the elderly
than in the middle-aged population.
Benzodiazepine derivatives, which
already have a long half-life as it is,
have a very long half-life in the elderly,
and the associated risk of accumulation
is high. Tiredness, impairment of
memory and other cognitive abilities,
confusion, muscle weakness, co-ordi-
nation problems and falling down are
generally reported adverse reactions
(7).
Impairment of memory and other
cognitive abilities, confusion and
behavioural disorders, in addition to
constipation, dryness of the mouth
and visual disturbances, are adverse
reactions in the elderly generally
Expert recommendations for medical care of the elderly have been issued in many countries, especially with regard to the
drugs which are to be avoided. The recommendations issued in Sweden in 2003 emphasise the avoidance, for example, of
long-acting benzodiazepines, i.e. diazepam, chlordiazepoxide and nitrazepam, potent anticholinergics, oral theophylline,
and quinine, because of the associated risk of adverse reactions. 
caused by potent anticholinergic
agents. The efficacy of anticholinergic
agents for the treatment of urinary
incontinence has not been proven in
the treatment of urinary incontinence
in the elderly. These are grounds for
avoiding the use of the above
mentioned agents (7).
Theophylline has a narrow thera-
peutic range, adverse effects and inter-
actions with several medicines. Proof
of its effect in the treatment of adult
onset asthma and of chronic obstruc-
tive pulmonary disease is inadequate.
Oral theophylline should therefore be
avoided. 
The adverse reactions of quinine
include confusion and thrombocytope-
nia. It is consequently considered a
drug to be avoided in the treatment of
the elderly (7).
Medicines for which correct
indications are necessary
The following section contains medici-
nal substances which are problematic
as to their adverse effects and interac-
tions and which, as studies show, are
prescribed to the elderly relatively
commonly without indications to jus-
tify their use. The necessity for critical
assessment in the prescription of anti-
inflammatory drugs, opioids, antipsy-
chotics, digoxin, loop diuretics and
serotonin-selective antidepressants is
emphasised. (7). 
Gastrointestinal ulcers and haemor-
rhages, fluid retention, cardiac insuffi-
ciency, reduced renal function and
cognitive disturbances are adverse reac-
tions caused by anti-inflammatory
analgesics in the elderly. Paracetamol is
a relatively safe medicinal substance for
the treatment of pain in the
musculoskeletal system in the elderly.
Anti-inflammatory analgesics should
not be used unless their use is associat-
ed with benefits greater than those
with paracetamol (7).
An opioid, e.g. codeine or tramad-
ol, may erroneously be prescribed for
long-term use without evaluation of
the effects of the treatment. The use of
opioids should always be based on a
specific diagnosis of the cause of the
pain, and the effects of the treatment
and adverse reactions should be moni-
tored. Tiredness, adverse cognitive
effects, confusion and falling down are
the adverse reactions of these drugs
exhibited in the elderly. The benefits of
the treatment must be bigger than the
adverse effects (7).
Codeine and tramadol are
prodrugs, which may be ineffective as
a result of the use of another medicine
or a genetic property. They are activat-
ed by the effect of enzyme cytochrome
P450 2D6. Fluoxetine, quinidine,
parecoxib and terbinafine are potent
inhibitors of this effect. They, includ-
ing celecoxib, several antipsychotic
drugs (e.g. haloperidol, risperidone
and phenothiazine derivatives), paroxe-
tine and amitriptyline impair the anal-
gesic effect of tramadol and codeine
(11). These drugs should not be used
concomitantly with codeine or
tramadol.
Tramadol is serotonergic and its use
concomitantly with an antidepressant
may cause a serotonin syndrome. Tra-
madol should not be prescribed if the
elderly patient is treated with an anti-
depressant. In the concomitant use of
these two drugs the patient should be
carefully monitored for any symptoms
of serotonin syndrome. They include,
for example, anxiety, restlessness,
hyperactivity, sleeplessness, confusion,
sweating, tremor, diarrhoea, co-ordina-
tion disorders and feverishness (11,
12).
The use of antipsychotics should be
limited to a fixed-term treatment of
psychosis and severe states of aggress-
iveness. The response and reactions
should be monitored. Cognitive disor-
ders, parkinsonism, akathisia, tardive
dyskinesia, sedation and orthostatism
are common adverse reactions to these
medicinal substances exhibited in the
elderly. Long-term use of antipsychot-
ics is commonly considered inappro-
priate medical treatment (7).
According to studies, loop-diuretics
are commonly used for oedema with-
out establishing the cause of the symp-
tom. Their use should be based on a
carefully established indication (7).
The importance of selective
prescription of serotonin-selective anti-
depressants is emphasised, because they
are mistakenly prescribed to elderly
patients suffering from mild states of
depression and even to grieving elderly
patients (7). There is no proof of their
effects in the treatment of mild states
of depression or in the improvement of
normal states of grief. The use of these
drugs has become more common.
They are only intended for the treat-
ment of severe or moderate states of
depression in conjunction with drug-
free therapies (13). The effects of anti-
depressants should be evaluated at reg-
ular intervals and treatment should
generally be fixed-term (7).
Duration of use
This section contains instructions for
the evaluation of the need for and
duration of treatment with certain
drug groups, i.e. benzodiazepine deriv-
atives and similarly acting medicinal
substances, anti-inflammatory
analgesics and irritant laxatives, which
are rather commonly inappropriately
prescribed for long-term use (7). 
Benzodiazepine derivatives and
medicinal substances with a similar
effect are used as sleeping pills in the
elderly, administered every night for
several months and even several years
contrary to the instructions for use.
There is no proof of positive effects of
their long-term use in the treatment of
sleeplessness. Benzodiazepine derivat-
ives and medicinal substances with a
similar effect should not be prescribed
for use every night for a period longer
than a month. For more long-term
use, there should be a special reason
(7). Positive effects of drug-free thera-
pies for treating sleeplessness have also
been found in the elderly (14). These
therapies should be introduced into
practice.
To prevent problematic gastro-
intestinal and other adverse reactions
caused by anti-inflammatory anal-
gesics, their daily use should be
restricted to a course of treatment last-
ing for a maximum of three months.
For the treatment of long-term pain,
the primary prescription should consist
of paracetamol (7).
Long-term use of irritant laxatives
may cause paralysis of the intestinal
wall muscles and paradoxical constipa-
tion. Their use should be restricted to
three weeks. The treatment of consti-
pation in elderly patients who have
suffered a stroke or who have Parkin-
son’s or some other severe neurological
disease, may require treatment for a
longer period (7).
Dosage 
The recommendations include those
for daily maximum doses of some
antipsychotic drugs. Exceeding these
maximum doses will increase the risk
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of adverse reactions without increasing
the positive therapeutic effects. The
doses of antipsychotic drugs are estab-
lished individually once the symptoms
and the circumstances of the patient
have been stabilised by treatment (7).
Multiple drug treatment
It is considered that the concomitant
use of some medicinal substances of
the same ATC Code should be avoid-
ed. The problems arising from the
concomitant use of two or more ben-
zodiazepine derivatives or medicinal
substances with a similar effect, two or
more antipsychotic agents, two or
more anti-inflammatory analgesics or
two or more opioids, are emphasised
because of the increased development
of adverse reactions without the
increase in positive therapeutic effects
(7).
Medicines to be avoided 
in the treatment of certain 
diseases
It is emphasised that the use of an
anti-inflammatory analgesic in the
treatment of arthrosis should be avoid-
ed if the efficacy of paracetamol has
not been tried first. Opioids should
only be prescribed if paracetamol or an
anti-inflammatory analgesic has been
found ineffective (7).
Elderly patients with dementia easi-
ly suffer from adverse CNS effects
caused by drugs. They should not be
prescribed potent anticholinergic
agents or long-acting benzodiazepine
derivatives. The use of other benzodi-
azepine derivatives, substances with a
similar effect and other sedatives
should also be restricted. It is empha-
sised that antipsychotics should only
be used for the treatment of psychotic
symptoms or severe states of aggress-
iveness.  The doses should be kept to a
minimum, the effects and adverse reac-
tions evaluated at set intervals and the
use should not be continued for several
years (7). The psychotic symptoms and
aggressiveness in many elderly demen-
tia sufferers are cured with the use of
antipsychotic drugs for a couple of
months (15).
Finnish examples of medical
treatment 
The use of benzodiazepines with a
long half-life and potent anticholiner-
gic agents is common. The concomi-
tant use of two or more benzodiaz-
epine derivatives or a substance with a
similar effect, and the concomitant use
of three or more antipsychotic agents,
are a reflexion of the problems associ-
ated with medical treatment of the
elderly in Finland (16, 17).
What should be done?
Finland needs recommendations for
the medical treatment of the elderly
based on the expertise and critical
views of experts in the field of
geriatrics, clinical pharmacology and
clinical pharmacy. Further training in
the medical treatment of the elderly
should be arranged for doctors and
other health care employees. Increase
in the training of geriatricians and the
establishment of departments and
units of geriatrics at the university and
central hospitals is necessary. Offices of
experts in clinical pharmacy should be
established at hospitals. Data systems
containing reports of drug interactions
should be introduced at all health care
institutions and pharmacies through-
out the country. The data systems
should be developed to incorporate the
availability of reports of the parallel use
of drugs and the use of drugs which
should be avoided in the elderly. In the
evaluation of renal function in the
elderly, a system using serum cystatine
C concentration assays should be
introduced. Specific guidelines for
drug doses appropriate to use in the
elderly are also required.
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This survey examines the impact on
pharmaceutical policies of the strate-
gies developed in Finland within the
administrative sector of the Ministry of
Social Affairs and Health and
compares them with the corresponding
policies in the other Nordic countries
and the EU. The survey serves as a
background review for the working
group.
Pharmaceutical policy 2010, a doc-
ument published by the Ministry of
Social Affairs and Health in Finland in
2003, was the first distinct policy doc-
ument discussing the aims of the phar-
maceutical sector. Among the objectiv-
es and schemes of the Ministry during
1988–2003 pharmaceutical services
were discussed merely as a restricted
part of the health care system, despite
the continuously increasing signific-
ance of drugs in both the treatment of
diseases and of symptoms, and the
costs involved.
In their health and drug policies
the Nordic countries have several simi-
larities. Key topics within health care
include the public health protection
and promotion and the increasing
costs of drugs. Drugs are usually dis-
cussed as a separate issue with primary
focus on costs and ways of reducing
them. In Finland the proportion of
drug costs amounted to almost 16% of
the total health care costs in 2003. 
At the EU level particular cause for
concern is created by the declining
innovation and competitiveness of the
European pharmaceutical industry
overall, and also by the introduction of
free internal markets in the medicinal
products sector. The important role of
the pharmaceutical industry in main-
taining European competitiveness has
also separated the pharmaceutical poli-
cy from the general health policy.
In the light of health policy docu-
ments, drugs and pharmaceutical ser-
vices in Finland appear to occupy a
conflicting position. The continuous
increase in drug costs poses a health
political problem. On the one hand,
economic advantages can be created
with drugs in the rest of the health
care sectors, e.g. reduction in person-
nel costs. This may, on the other hand,
conflict with the aims associated with
improving the welfare and relative sta-
tus of disadvantaged population
groups.
Various cost management methods
include supervision of drug pricing
processes, the principles of the drug
reimbursement system and the moni-
toring and guidelines associated with
prescribing. Pharmacotherapies and
pharmaceutical services should in
future be viewed as an integrated part
of the health care system because, if
wisely managed, pharmacotherapies
can in fact reduce the total health care
costs. Great expectations are at present
attached to the monitoring and guide-
lines of drug prescription. It appears
nevertheless that drug cost problems
are continuously becoming a major
concern with regard to the multi-chan-
nel financing system of drugs and in
the discrepancies among its various
parts.
In English
Medicines in the focus of health policies
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Planning for Pharmaceutical Policies
National Agency for Medicines
The objective of the working group which has been set up at the National
Agency for Medicines in 2005 and is involved in the general planning of phar-
maceutical services is to carry out studies and produce reviews in support of deci-
sion making and public discussion in relation to pharmaceutical policies.
Judging by the literature, the most
common adverse reactions caused by
nitrofurantoin include gastrointestinal
symptoms (nausea, abdominal pain
and diarrhoea). Skin symptoms are
estimated to have occurred in 1–2% of
patients treated with nitrofurantoin,
and other reactions indicative of
hypersensitivity reported have included
drug fever and occasionally anaphylax-
is. Adverse liver effects (increased liver
values and hepatitis) are relatively rare.
Large doses have occasionally been
associated with polyneuropathy (90%
of these patients have suffered from
renal failure). Isolated cases of benign
intracranial pressure have been report-
ed, and the most common CNS symp-
toms have included headache and ver-
tigo. Blood count changes and
haemolytic anaemia are also a possibili-
ty.
Nitrofurantoin causes acute
pulmonary damage more often than
any other drug. About 90% of the pul-
monary reactions are acute. The severe
acute form is estimated to have
occurred in one patient per 5,000 pre-
scriptions. In long-term users, one in
750 patients is estimated to develop a
chronic pulmonary reaction so serious
that the patient is hospitalised due to
the disorder. The acute form occurs
typically in women at the age of 40–50
years, whereas the chronic reaction is
more common in older patients.
An acute pulmonary reaction
caused by nitrofurantoin is independ-
ent of dose, and the symptoms occur
within a couple of hours or days of the
start of the therapy. The symptoms
include fever, dyspnoea and cough,
possibly associated with skin rash.
Chest pain and cyanosis may also
occur. Blood leukocytosis and
eosinophilia are common, and the
CRP may also be elevated. Pulmonary
imaging may show  alveolar or intersti-
tial infiltration; pleural effusion may
also be present.
A chronic reaction develops follow-
ing weeks or years (often more than
half a year) of using the drug.
Dyspnoea and cough are also
symptoms of a chronic reaction, with
the added symptoms of tiredness and a
declining general condition.
Pulmonary imaging usually reveals
bilateral diffuse infiltration in the basal
segments, but eosinophilia is not usu-
ally present in the blood differential
count. Testing for the rheumatoid fac-
tor or antinuclear antibodies may be
positive. A chronic reaction may be
more difficult to recognise because of
the slow development of symptoms,
and the patient’s treatment, possibly
long-term, is not readily suspected.
Cases of death have been reported,
associated with both acute and chronic
reactions. BOOP (i.e. cryptogenic
organised pneumonia, COP) may also
be associated with the use of nitrofu-
rantoin. Other types of pulmonary
damage have also been described, e.g.
rare cases of alveolar haemorrhage
(www.pneumotox.com).
Case 1. 
Acute pulmonary reaction
A 28-year-old female, otherwise
healthy except for recurrent urinary
tract infections, was hospitalised in the
30th week of pregnancy, having been
admitted from a maternity clinic due
to fever and dyspnoea. A week prior to
the incident she had been started on
nitrofurantoin therapy for urinary tract
infection. On arrival her general condi-
tion was good, and auscultation of the
lungs revealed nothing out of the ordi-
nary. The blood count showed leuko-
cytosis, but no eosinophilia. Elevation
of the CRP was also present; 132 mg/l.
The findings on pulmonary imaging
were scarce, but the contour of the
heart at the apex of the right medial
segment was indistinct. 
Nitrofurantoin-induced pulmonary
reaction was suspected clinically, since
dyspnoea associated with the use of
nitrofurantoin had occurred in the
patient previously. Infection was never-
theless also suspected and the patient
was hospitalised. The therapy consisted
of a single dose of 40 mg methylpred-
nisolone intravenously combined with
antibiotic treatment. Nitrofurantoin
was discontinued. Dyspnoea abated
quickly and fever also dropped within
24 hours. Three days from the start of
treatment, the CRP fell to 45 mg/l and
the patient was discharged symptom-
free; cefalexin therapy was continued
for another 10 days. In this patient,
the symptoms (fever, dyspnoea) are
indication of an acute pulmonary reac-
tion caused by nitrofurantoin, so is
dyspnoea which occurred earlier in
association with the use of this drug.
With an atypical pulmonary imaging
finding and absence of eosinophilia,
and also symptoms and findings
indicative of an infection, the diagnosis
remains nevertheless slightly uncertain.
Nitrofurantoin was not recommended
thereafter.
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Nitrofurantoin and pulmonary adverse reactions
Nitrofurantoin is widely used because it works well in the context of microbial
resistance and is cost-effective in the prophylaxis of urinary tract infection. In the
Finnish Current care guideline (from the year 2000) for urinary tract infections,
nitrofurantoin is recommended as the primary therapy in cystitis, alongside
trimethoprim and pivmecillinam.
Case 2. 
Chronic pulmonary reaction
A 77-year-old male with hypertension,
coronary artery disease, paroxysmal
atrial fibrillation and prostate cancer,
was given nitrofurantoin as prophylac-
tic treatment for urinary tract infection
(the patient has had a percutaneous
catheter in the urinary bladder for a
number of years). The medication con-
sisted additionally of Emconcor 5 mg
x 1, Primaspan 100 mg x 1, Diovan
comp x 1, Ismox 20 mg x 1, Casodex
50 mg x 1, Norvasc 5 mg x 1 and Pro-
cren injections every 12 weeks. After
about four months of nitrofurantoin
therapy (75 mg x 1) the patient was
transferred from a health centre to a
hospital due to a dry cough and inter-
mittent fever that had lasted for a week
and a half. The symptoms had been
treated with antibiotics without a
response. The general condition was
beginning to decline. Pulmonary imag-
ing showed extensive predominantly
basal infiltratations bilaterally. An
HRCT study showed changes which
could have been indicative of a chronic
reaction to a drug, for example; some
ground-glass opacities, peripheral sub-
pleural consolidations, and interlobular
interstitial thickenings, with a little
pleural fluid bilaterally. Blood tests
revealed elevated ESR (95) and CRP
(118 mg/l). Leukocytosis, anaemia or
blood eosinophilia were not found. On
arrival at hospital that the patient was
clearly hypoxaemic (aB-pO2 6,6 kPa)
and in need of supplementary oxygen.
Nitrofurantoin was discontinued, and
due to severe dyspnoea the patient was
given intravenous methylprednisolone
40 mg x 3 for two days, followed by
predisolone 40 mg/day orally. Antibi-
otic therapy was given for 24 hours
intravenously, followed by oral admin-
istration for one week. After 5 days of
treatment in hospital the patient felt
better but was still suffering from
breathlessness and needed supplemen-
tary oxygen. CRP had fallen to 22
mg/l, and the patient had no fever.
Cortisone therapy was continued for a
total of four weeks reducing the dose
decrementally, and the patient was
transferred back to the health centre
from where he was later discharged. A
follow-up appointment two months
later showed clear improvement in
condition, even though dyspnoea was
still present on exertion. On
pulmonary imaging the changes had
clearly thinned out, and the
hypoxaemia had also been relieved
(aB-pO2 10.4 kPa).
Nitrofurantoin in Finnish ADR
data
The adverse drug reaction register was
processed for reports associated with
the use of nitrofurantoin over a period
of 32 years. During that period, nitro-
furantoin had been reported on 740
occasions (4% of all reports, the total
number being 18,923). The reports
peaked in the 1970’s when the propor-
tion of reports on nitrofurantoin var-
ied between 8% and 13% of all
reports, declining relatively evenly
down to a variation of between 1%
and 3% in the 2000’s. Females were
involved in 680 of the reports and
males in 60, reflecting the user group
of nitrofurantoin. Of all the patients
providing the material 394 were over
65 years of age (53%). Four reports
involved patients under the age of 10,
all of whom were girls. The youngest
of the girls, a 1-year-old, suffered from
discolouration of the teeth, a 3-year-
old had a rash, a 6-year-old suffered
from joint pain and a 9-year-old had
developed a pulmonary infiltrate.
Pulmonary reactions
In 1974, in as many as 85% of the
reports involving adverse reactions of
the respiratory organs the suspected
drug was nitrofurantoin, but this pro-
portion has since diminished to
between 10% and 18% in the 2000’s.
Of all the reports on nitrofurantoin,
513 were of adverse pulmonary reac-
tions and the remaining 227 of adverse
reactions in other system organ classes.
Fig. 1 shows the total number of
reports of adverse reactions caused by
nitrofurantoin, and the pulmonary
reactions among these. 
The adverse pulmonary reactions
are shown in Fig. 2 with the classifica-
tion arranged according to the most
significant adverse reaction, i.e., if the
report involved a pulmonary fibrosis
and dyspnoea, the adverse reaction of
the report would be classified as pul-
monary fibrosis.
The majority of the adverse
pulmonary reactions involved unspeci-
fied pulmonary infiltration, (268
reports, 16 of which also included
eosinophilia in the blood count), while
eosinophilic pulmonary infiltration
was mentioned in 34 reports. The sec-
ond highest number of reports received
were about pulmonary fibrosis (83),
and alveolitis was the adverse reaction
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Fig. 1. ADR reports associated with the use of nitrofurantoin in 1973–2004
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reported in 26 cases. Symptoms alone
– cough and dyspnoea, either in com-
bination or alone – were reported on
92 occasions.
Other ADRs
Liver effects were described in 55 of
the 227 reports involving other system
organ classes (30 reports on pulmonary
effects also included a mention of a
liver effect), adverse skin reactions were
described in 85 reports, and fever was
included in 62 reports which did not
mention liver or skin reactions. Fever
as a symptom was often also mention-
ed together with other adverse
reactions. Among all the reports on
adverse reactions caused by nitrofuran-
toin, 12 mentioned symptoms of
polyneuropathy.
Conclusion
Even though the pulmonary damage
caused by nitrofurantoin (‘nitrofuran-
toin lung’) has been known for a long
time (the first case in the literature dat-
ing back to the 1950’s), some of the
cases reported to the National Agency
for Medicines reveal nevertheless the
difficulty of detecting the causal rela-
tionship. Patients using nitrofurantoin
should be advised to contact a doctor
immediately upon detection of symp-
toms involving the respiratory organs.
Nitrofurantoin therapy must in conse-
quence be immediately discontinued.
The symptoms of an acute reaction are
usually quickly reversed after discon-
tinuation of therapy, but a chronic
reaction may result in the development
of permanent pulmonary fibrosis. Cor-
ticosteroids have been used in the
treatment of serius symptoms without
controlled evidence of benefit in the
(chronic) reaction. In future, nitrofu-
rantoin is of course contraindicated. 
The consumption of nitrofurantoin
is shown in Fig. 3. The consumption
has remained fairly steady during the
past 15 years. 
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A considerable proportion of the phar-
maceutical industry budget is used for
the marketing of medicinal products. It
is estimated that the share of drug pre-
sentations in the entire marketing bud-
get of a company may be as high as fifty
percent (1). Drug presentations are an
important and also obviously effective
form of marketing, especially in the
marketing targeted at doctors. Doctors
feel that they are receiving plenty of use-
ful drug information from the pharma-
ceutical industry, but they nevertheless
do not consider that marketing would
influence solely their own practices
when prescribing (1-8).
In Finland, drug marketing is regu-
lated by the Medicines Act and Decree.
According to the Medicines Act, drug
marketing should always be based on
the approved summary of product char-
acteristics (SPC) of the medicinal prod-
uct and the information it contains. As
with all other aspects of drug marketing,
drug presentations should, according to
law, disclose all information relative to
the drug consistent with its SPC, on the
basis of which it is then possible for the
individual to have an accurate percep-
tion of the composition and medical
purpose of the drug.
This study aimed at explaining the
extent to which the properties essential
to the use of a drug are introduced in
the printed material available at drug
presentations. Another aim was to find
out whether drugs are marketed
through the distribution of information
which is not based on the approved
SPC.
Data and methods
The study was restricted to the actively
marketed group of angiotensin-receptor
antagonists. All MA holders of drugs of
this group on the market were requested
to submit the printed material they used
at drug presentations during 2003. At
the beginning of year, nine medicinal
products of this group had a valid mar-
keting authorisation. Six of these, five
medicinal products of which had been
marketed to doctors, were available on
the Finnish market in September 2003.
Instead of the trade names letters from
A to E are used. 
The marketing material used at drug
presentations often consists of slide
shows, leaflets, dose cards and scientific
papers. This study focused only on
slides and leaflets handed out to the par-
ticipants. The factual contents of slides
were of particular interest in the study,
since the main attention at any drug
presentation event is focused on the fac-
tual contents of slides, which usually
serve as the focal point of details which
the companies wish to emphasise in
their drugs. 
Grounds of evaluation
- How diverse was the presentation of
the most essential details of the medici-
nal product contained in its SPC? The
warnings and details of interaction with
other medicinal products are the
sections of special importance in view of
patient safety.
- Studies discussed in the marketing
material including, for example, infor-
mation about new therapeutic
indications.
- The association between the medicinal
product and the treatment recommen-
dations, and the way in which drug-free
treatment was introduced.
A direct comparison was made
between the details of the marketing
material and the approved SPC, includ-
ing an assessment of whether the mater-
ial contained the essential details about
the drug.
Results
The marketing material studied consist-
ed, to a large extent, of the demonstra-
tion of results of clinical studies. A var-
ied amount of information consistent
with the approved SPC of the medicinal
products was also disclosed.
Comprehensive information about dos-
ing was made available. The indication
approved for the medicinal product and
the risk factors associated with the use
of the drug, however, received minor
attention. Table shows the number of
properties mentioned in the slides of the
medicinal products. It also serves as a
general outline of differences between
the slide shows of the various drugs
studied.
Information consistent with the
SPC
Essential hypertension is the therapeutic
indication for all the medicinal products
studied; the indications for one product
also include cardiac failure and the
treatment of kidney disease in patients
with type 2 diabetes. The slide material
of only one product disclosed the thera-
peutic indication for the drug; the rest
of them, except for one, mentioned the
therapeutic indication in the abstract of
the SPC.
The drug information leaflets of
medicinal products included in this
study had almost totally omitted men-
tioning any warnings or drug inter-
actions. The contraindications of
angiotensin-receptor antagonists are to a
large extent associated with liver and
kidney diseases, so the dosages will in
any case be especially checked. Even
though some of the risk factors were
mentioned in the leaflets, they were
missing in the slides, which can be con-
sidered a shortcoming.
Angiotensin-receptor antagonists
have relatively few interactions with
other medicinal substances. There are,
however, a couple of medicinal sub-
stances which in the light of experience
in the use of ACE inhibitors are
thought to be influenced by angioten-
sin-receptor antagonists. These sub-
stances include, for example, lithium,
anti-inflammatory analgesics and medic-
inal substances with an effect on the
potassium concentration. For example,
all products of the angiotensin-receptor
antagonist group, except one, may
according to the SPC increase the plas-
ma lithium concentration up to a toxic
level. This effect was not mentioned in
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the slides of any of the products; the
interaction was mentioned in the
abstract of the SPC in only one product
leaflet.
Angiotensin-receptor antagonists are
usually relatively well tolerated (9). The
official SPCs of the drugs included in
this study also include a mention of the
fact the drugs have, according to stud-
ies, been as well tolerated as the place-
bos. As these drugs are not metabolised
via the CYP enzyme, this fact has
understandably been given little atten-
tion.
Details of the price of and
reimbursement for all medicinal prod-
ucts were disclosed in some part of the
material, but the date of preparation of
the leaflet was very rarely included. As
the marketing material contained sec-
tions (e.g. leaflets) which had been pre-
pared at various times, a date of prepa-
ration would make it easier to focus on
the most recent changes relative to the
product. The Medicines Act also stipu-
lates the obligation of mentioning the
date of preparation of leaflets.
Wider therapeutic indications?
The slides and leaflets of all the prod-
ucts included in the study mentioned
repeatedly the effect of the drug on the
blood pressure. The studies discussed in
the leaflets of all products, except one,
included this among the approved
indications. The leaflet of one product
contained an extensive description of a
study which had been carried out in
patients with cardiac failure. The only
approved indication of the product was
essential hypertension. The official ther-
apeutic indication was only included in
the abstract of the SPC of the product.
As the official indication of one
angiotensin-receptor antagonist is car-
diac failure, the intention was probably
to widen the indication of yet another
product. The indication has not, how-
ever, been approved in the process of
granting the marketing authorisation,
and marketing of this type is therefore
misleading.
Treatment recommendations
and drug-free therapy
National Current care recommen-
dations for treatment and drug-free
therapies received only very little atten-
tion in the material that was studied.
The material of two products studied
included a separate brochure on current
care guidelines for hypertension, but
neither the leaflets nor the slides men-
tioned the national recommendations at
all. However, a slide and one brochure
of one product included the treatment
recommendation of the ADA (Ameri-
can Diabetes Association), which puts
the angiotensin-receptor antagonists as
the primary choice for patients with
type 2 diabetes with hypertension and
microalbuminuria. Finnish recommen-
dations for treatment of diabetics with
nephropathy (independently of type of
diabetes) include either an ACE-
inhibitor or an angiotensin-receptor
antagonist. Microalbuminuria is consid-
ered a sign of developing nephropathy,
and consequently, the recommendation
is not very far from the Finnish recom-
mendation for treatment, but neverthe-
less it is preferable to include any
national recommendations in the mar-
keting material. To bring up a foreign
recommendation for treatment may
also be interpreted as an attempt to
broaden the user groups of the product
in comparison with the national treat-
ment recommendation.
The current care guideline also
stresses the importance of drug-free
therapy for hypertension (10). In the
marketing material under study its
mention had been omitted altogether,
except for one product. One slide and
two brochures of one product stressed
the importance of change in living
habits.
Conclusions
This study shows that the presenta-
tions of essential drug properties in the
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The mater ia ls  used in  drug presentat ions  
Medicinal product A B C D1* D2* E
Slide shows 1 1 1 1 1 1
Leaflets 1 1 2 0 0 3
Clinical data
Indications 1 0 0 0 0 0
Dosage and administration 5 1 0 3 0 2
Contraindications 0 0 0 0 0 0
Warnings and precautions 0 0 0 0 0 0
Interactions 1 0 1 0 0 1
Pregnancy and lactation 0 0 0 0 0 0
ADRs 2 0 1 0 0 1
Pharmacological data
Pharmacodynamic properties 1 0 0 0 0 3
Pharmacokinetic properties 2 1 1 0 0 0
Further details
Reimbursement status 1 0 1 0 1 0
Packages and prices 1 0 1 0 1 0
Leaflet’ date 0 0 0 0 0 1
Total per medicinal product 14 2 5 3 2 8
D 1 = slide show of product D, spring 2003, D 2 = slide show of product D, autumn 2003
marketing material are not adequately
varied;  they fail to disclose, for exam-
ple, the indications, warnings and
inter-actions. Risk factors, in particular,
associated with the use of the medicinal
products, were almost totally omitted.
Several of the studies introduced were
associated with other heart diseases
such as cardiac failure, for example, and
consequently, these materials fail to
give a clear impression of the indication
for which the product is officially
approved. The positive properties of
the products in respect of efficacy and
tolerability are extensively discussed,
but risk factors associated with the
products are hardly dealt with in the
material.
The content of drug information
given at drug presentations has been
the object of some studies ever since
the 1970’s. The results have been quite
similar to those of this current study
(11-14). A drug is introduced in a very
positive light, but any negative effects
associated with the use of the drug are
often left without even a mention (15).
Adverse effects or contraindications
were hardly mentioned at the presenta-
tions; however, there are relatively few
of them in the drugs of this group. Fac-
tors affecting the choice of the correct
drug therapy were also touched upon
very little at the drug presentations.
The marketed drug is presented as the
best choice, although this may not in
fact be the case. Introductions of drug-
free therapies are also very rare (13).
In the light of these studies, the
drug information given at drug presen-
tations proves to be inadequate in
many ways (13). Safety aspects in par-
ticular are often ignored, and should
any reference be made to safety it is
only done in a way which benefits the
marketed product. The information
given at drug presentations does,
indeed, convey a picture of the drug
properties which is too positive (16).
As this study only examined the
printed material used at drug presenta-
tions, it is not possible to draw conclu-
sions based on it concerning what is
being said at drug presentations as a
whole. A pharmaceutical sales represen-
tative may ignore some of the informa-
tion contained in the slides, or he or
she may verbally quote data which are
not found anywhere in the written
material. Slides and leaflets are never-
theless very widely used at drug presen-
tation events, and this study is conse-
quently a good starting point for assess-
ing the aspects that a pharmaceutical
company wishes to emphasise in its
products. Since almost all of the risk
factors associated with the use of the
drugs were missing in the printed
material, it may be assumed that they
have not been thoroughly discussed
verbally either.
The proceedings at a drug presenta-
tion event are naturally influenced by
the keenness to participate, or the lack
of it, of the doctors present. Doctors
are certainly in a position to receive
from the pharmaceutical sales represen-
tatives good and accurate information
also about the risks involved in the use
of the products, but this study shows
that unless doctors are active
themselves the drug marketing targeted
at them will be conveyed to them in a
very positive light.
For drug presentation events to be
of benefit to doctors, the information
given at the presentations should be
adequately diverse with regard to both
the properties of the drugs and the
treatment recommendations.
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State Food and Drug Agency from China visits Finnish National Agency for Medicines 
In September, the NAM had a pleasure of hosting six delegates from the State Food and Drug Agency. Director General
Hannes Wahlroos gave an introduction to the NAM. The other topics of interest included the Finnish pharmaceutical services
system and classification of prescription and
non-prescription medicines, which were
presented by Senior Pharmaceutical Inspec-
tor Sami Paaskoski and Senior Medical
Officer, Dr. Veijo Saano. After Finland, the
delegation was to continue further north to
Iceland. 
Wahlroos explained the delegation, led by Deputy
Director Gao Xiang and Deputy Division Director
Yang Ai-Dong, the variety of functions of the NAM.
Tr
an
sl
at
io
n 
M
er
vi
 M
oi
sa
nd
er
